Sensorium Therapeutics

Sensorium Therapeutics is developing FDA-approved psychoactive drugs for treating mental illnesses. There is a growing unmet need in mental health and neurological diseases, with existing treatments carrying serious side effects and risks. By leveraging knowledge of natural compounds in humans for centuries, Sensorium is advancing novel chemical entities (NCEs) capable of transforming current CNS treatment options. The platform involves the integration of their library of more than 300,000 natural compounds for molecular screening with their proprietary machine learning to simulate therapeutic outcomes and classify mechanisms of action. Sensorium’s lead program, SENS-01, is a highly selective fast-acting anxiolytic that is in preparation for clinical studies.

Jobs: